ArticleFrontiers in immunology2019
Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness.
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 50 citations in OpenAlex.
- Roles of V-domain Ig suppressor of T-cell activation-mediated immunoregulation in tumor immune escape (Review).Oncology letters · 2026Review
- The role of VISTA engagement in limiting neutrophil-mediated inflammation.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Article
- Macrophages suppress CD8 + T cell cytotoxic function in triple negative breast cancer via VISTA.British journal of cancer · 2025Article
- Abnormal proportions and functions of myeloid-derived suppressor cells in peripheral blood of patients with diffuse large B-cell lymphoma.BMC cancer · 2025Article
- VISTA-mediated immune evasion in cancer.Experimental & molecular medicine · 2024Review
- H-VISTA Immunohistochemistry Score Is Associated with Advanced Stages in Cutaneous and Ocular Melanoma.International journal of molecular sciences · 2024Article
- VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses.Experimental hematology & oncology · 2024Article
- VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms.Cell reports · 2024Article
- Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes.The Journal of investigative dermatology · 2024Article
- Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma.Frontiers in immunology · 2024Article
- VISTA in hematological malignancies: a review of the literature.Frontiers in immunology · 2024Review
- VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy.Cancer cell international · 2023Review
- The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease.Nature communications · 2023Article
- VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance.Cancer immunology research · 2023Article
- Spatial profiling of the placental chorioamniotic membranes reveals upregulation of immune checkpoint proteins during Group BFrontiers in cellular and infection microbiology · 2023Article
- PSGL-1: a novel immune checkpoint driving T-cell dysfunction in obstructive sleep apnea.Frontiers in immunology · 2023Article
- Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights.Frontiers in oncology · 2023Review
- Spatial proteomics identifies a spectrum of immune dysregulation in acquired bone marrow failure syndromes.Frontiers in immunology · 2023Article
- A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
The role of negative checkpoint regulators (NCRs) in human health and disease cannot be overstated. V-domain Ig-containing Suppressor of T-cell Activation (VISTA) is an Ig superfamily protein predominantly expressed within the hematopoietic compartment and has been studied for its role in the negative regulation of T cell responses. The findings presented in this study show that, unlike all other NCRs, VISTA deficiency dramatically impacts on macrophage cytokine and chemokine production, as well as the chemotactic response of VISTA-deficient macrophages. A select group of inflammatory chemokines, including CCL2, CCL3, CCL4, and CCL5, was strikingly elevated in culture supernatants from VISTA KO macrophages. VISTA deficiency also altered chemokine receptor recycling and profoundly disrupted myeloid chemotaxis. The impact of VISTA deficiency on chemotaxis
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.